Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:AVXL NASDAQ:IMNM NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$17.65-5.0%$19.63$15.47▼$36.37$753.77M1.17282,832 shs1.52 million shsAVXLAnavex Life Sciences$8.46-2.4%$10.29$5.03▼$14.44$744.70M0.83960,190 shs1.91 million shsIMNMImmunome$9.39-4.7%$10.00$5.15▼$15.51$857.39M1.921.16 million shs2.44 million shsVORVor Biopharma$27.24-10.4%$40.37$2.62▼$65.80$3.45B2.05380,475 shs654,392 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-5.01%-10.45%-8.41%-30.02%-25.18%AVXLAnavex Life Sciences-2.42%-9.71%-12.60%-6.93%+53.82%IMNMImmunome-4.67%+1.95%-1.88%+7.31%-39.42%VORVor Biopharma-10.39%-21.72%-38.09%+466.79%+45.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$17.65-5.0%$19.63$15.47▼$36.37$753.77M1.17282,832 shs1.52 million shsAVXLAnavex Life Sciences$8.46-2.4%$10.29$5.03▼$14.44$744.70M0.83960,190 shs1.91 million shsIMNMImmunome$9.39-4.7%$10.00$5.15▼$15.51$857.39M1.921.16 million shs2.44 million shsVORVor Biopharma$27.24-10.4%$40.37$2.62▼$65.80$3.45B2.05380,475 shs654,392 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-5.01%-10.45%-8.41%-30.02%-25.18%AVXLAnavex Life Sciences-2.42%-9.71%-12.60%-6.93%+53.82%IMNMImmunome-4.67%+1.95%-1.88%+7.31%-39.42%VORVor Biopharma-10.39%-21.72%-38.09%+466.79%+45.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.00Buy$39.14121.77% UpsideAVXLAnavex Life Sciences 3.00Buy$44.00420.09% UpsideIMNMImmunome 3.00Buy$22.89143.76% UpsideVORVor Biopharma 2.56Moderate Buy$121.33345.42% UpsideCurrent Analyst Ratings BreakdownLatest VOR, AVXL, IMNM, and AVBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$21.009/10/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.009/10/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.009/5/2025IMNMImmunomeCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.008/27/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.008/25/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/25/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/22/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.008/22/2025IMNMImmunomeEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$18.008/18/2025AVBPArriVent BioPharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/14/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$7.65 per shareN/AAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AIMNMImmunome$9.04M90.41N/AN/A$2.27 per share4.14VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$80.49M-$4.02N/AN/AN/AN/A-55.40%-51.97%11/13/2025 (Estimated)AVXLAnavex Life Sciences-$43M-$0.57N/AN/AN/AN/A-45.67%-40.21%N/AIMNMImmunome-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%11/12/2025 (Estimated)VORVor BiopharmaN/A-$13.66N/AN/AN/AN/AN/AN/AN/ALatest VOR, AVXL, IMNM, and AVBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q3 2025AVXLAnavex Life Sciences-$0.13-$0.16-$0.03-$0.16N/AN/A8/11/2025Q2 2025AVBPArriVent BioPharma-$0.70-$0.90-$0.20-$0.90N/AN/A8/6/2025Q2 2025IMNMImmunome-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A12.7412.74AVXLAnavex Life SciencesN/A8.938.93IMNMImmunomeN/A12.1312.13VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%AVXLAnavex Life Sciences31.55%IMNMImmunome44.58%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma18.58%AVXLAnavex Life Sciences11.40%IMNMImmunome7.69%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4040.57 million33.03 millionN/AAVXLAnavex Life Sciences4085.89 million76.10 millionOptionableIMNMImmunome4087.04 million80.35 millionOptionableVORVor Biopharma140126.68 million65.45 millionNot OptionableVOR, AVXL, IMNM, and AVBP HeadlinesRecent News About These CompaniesVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 447,278 Shares3 hours ago | marketbeat.comVor Biopharma trading halted on Thursday, news pendingSeptember 19 at 7:21 AM | msn.comVor Biopharma trading halted, news pendingSeptember 19 at 7:21 AM | msn.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 18 at 2:30 AM | marketbeat.comHead to Head Survey: Prime Medicine (NASDAQ:PRME) versus Vor Biopharma (NYSE:VOR)September 18 at 2:45 AM | americanbankingnews.comResults of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual MeetingSeptember 17 at 9:00 PM | prnewswire.comVor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEMSeptember 17 at 4:15 PM | globenewswire.comReprogrammed Interchange Llc Sells 284,805 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 16, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Sells $525,000.00 in StockSeptember 16, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Sells $656,000.00 in StockSeptember 16, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,805 SharesSeptember 16, 2025 | insidertrades.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 464,421 Shares of StockSeptember 12, 2025 | marketbeat.comReprogrammed Interchange Llc Sells 350,000 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 12, 2025 | marketbeat.comReprogrammed Interchange Llc Sells 449,226 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 12, 2025 | marketbeat.comVor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 12, 2025 | globenewswire.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 350,000 Shares of StockSeptember 11, 2025 | insidertrades.comWe Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth CarefullySeptember 7, 2025 | finance.yahoo.comOMERS ADMINISTRATION Corp Takes Position in Vor Biopharma Inc. $VORSeptember 7, 2025 | marketbeat.comVor Bio Appoints Adi Osovsky, S.J.D. as General CounselSeptember 2, 2025 | globenewswire.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 611,647 Shares of StockAugust 30, 2025 | insidertrades.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,190 SharesAugust 28, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025Shopify’s Risk-Reward Profile Is Suddenly Red HotBy Sam Quirke | August 22, 2025The Most Upgraded Stocks in Q3: Good News for the S&P 500By Thomas Hughes | September 17, 2025Why Seagate Is Wall Street's New Favorite AI Infrastructure PlayBy Jeffrey Neal Johnson | September 18, 2025VOR, AVXL, IMNM, and AVBP Company DescriptionsArriVent BioPharma NASDAQ:AVBP$17.65 -0.93 (-5.01%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$17.75 +0.10 (+0.57%) As of 09/19/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Anavex Life Sciences NASDAQ:AVXL$8.46 -0.21 (-2.42%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$8.50 +0.04 (+0.47%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Immunome NASDAQ:IMNM$9.39 -0.46 (-4.67%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$9.36 -0.03 (-0.31%) As of 09/19/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Vor Biopharma NYSE:VOR$27.24 -3.16 (-10.39%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$27.02 -0.22 (-0.79%) As of 09/19/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
